Report : Europe Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)
The others segment by type is estimated to lead the market growth during the forecast period.
According to a new market research study of “Europe Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Indication, Distribution Channel, and Country.” The Europe carbapenem-based antibiotics market is expected to reach US$ 1,469.86 million by 2028 from US$ 1,128.37 million in 2021; it is estimated to grow at a CAGR of 3.8% from 2021 to 2028. The report highlights trends prevailing in the Europe carbapenem-based antibiotics market and the factors driving market along with those that act as hindrances.
Antimicrobial resistance (AMR) has become a significant threat worldwide. Due to environmental factors such as exposure to antibiotics and spontaneous mutations, bacteria are becoming highly resistant to many antibiotics. Therefore, various strategies are designed to measure and control the spread of AMR. Several governments and healthcare authorities implement constructive plans to combat such critical situations. In 2017, the government of Germany announced the launch of the Global R&D Collaboration Hub to oppose AMR to focus on bridging gaps in the new developments. In January 2019, the UK government launched its strategy to deal with AMR. The UK's government has a 5-year national action plan to deal with antimicrobial resistance. Also, it has the vision to reduce AMR by 2040. The plan was developed across the governments, including Scotland, Wales, and Northern Ireland, and their agencies and administrations with the support of a range of stakeholders.
In April 2020, Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam. It is a broad-spectrum beta-lactamase inhibitor that restores the activities of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). However, it is an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam. Under the collaboration, GARDP and Venatorx look forward to developing cefepime-taniborbactam. The combination is under a phase 3 cUTI trial. Additionally, clinical trials in adults with multidrug-resistant infections and clinical development activities and trials to enable cefepime-taniborbactam for children, including newborns with severe bacterial infections, are being conducted. Such activities by public and private partnerships are projected to offer lucrative opportunities for the growth of the carbapenem-based antibiotics market during the forecast period.
The Europe carbapenem-based antibiotics market, by type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. Based on indication, the Europe carbapenem-based antibiotics market has been segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. Based on distribution channel, the Europe carbapenem-based antibiotics market has been segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Geographically, the Europe carbapenem-based antibiotics market is sub-segmented into Italy, France, UK, Germany, Spain and Rest of Europe.
ACS Dobfar S.p.A, Iterum Therapeutics plc, Aurobindo Pharma Ltd, Gland Pharma Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Savior Lifetec, Pfizer Inc. and Spero Therapeutics are among the leading companies operating in the North America carbapenem-based antibiotics market.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org